The stock of Acorda Therapeutics Inc (NASDAQ:ACOR) is a huge mover today! About 162,345 shares traded hands. Acorda Therapeutics Inc (NASDAQ:ACOR) has declined 29.64% since March 15, 2016 and is downtrending. It has underperformed by 35.12% the S&P500.
The move comes after 5 months positive chart setup for the $942.42M company. It was reported on Oct, 18 by Barchart.com. We have $27.54 PT which if reached, will make NASDAQ:ACOR worth $339.27M more.
Analysts await Acorda Therapeutics Inc (NASDAQ:ACOR) to report earnings on October, 27. They expect $-0.21 EPS, down 290.91% or $0.32 from last year’s $0.11 per share. After $-0.13 actual EPS reported by Acorda Therapeutics Inc for the previous quarter, Wall Street now forecasts 61.54% negative EPS growth.
Acorda Therapeutics Inc (NASDAQ:ACOR) Ratings Coverage
Out of 2 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Acorda Therapeutics has been the topic of 8 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Tuesday, August 25 by Stifel Nicolaus. JP Morgan maintained the shares of ACOR in a report on Tuesday, August 25 with “Neutral” rating. The rating was initiated by Raymond James with “Market Perform” on Tuesday, September 1. Goldman Sachs initiated Acorda Therapeutics Inc (NASDAQ:ACOR) rating on Wednesday, March 30. Goldman Sachs has “Neutral” rating and $23 price target. The firm has “Outperform” rating by Cowen & Co given on Tuesday, August 25. TheStreet downgraded the shares of ACOR in a report on Tuesday, August 25 to “Buy” rating. The rating was initiated by Aegis Capital with “Buy” on Tuesday, September 1. The firm earned “Buy” rating on Wednesday, January 6 by Aegis Capital.
According to Zacks Investment Research, “Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company’s lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.”
Insitutional Activity: The institutional sentiment decreased to 1.13 in 2016 Q2. Its down 0.28, from 1.41 in 2016Q1. The ratio turned negative, as 32 funds sold all Acorda Therapeutics Inc shares owned while 45 reduced positions. 14 funds bought stakes while 73 increased positions. They now own 43.11 million shares or 7.66% less from 46.68 million shares in 2016Q1.
Meeder Asset Management has 2,259 shares for 0.01% of their US portfolio. Martingale Asset Management Lp holds 11,092 shares or 0% of its portfolio. Manufacturers Life Insurance The last reported 29,192 shares in the company. Teachers Retirement System Of The State Of Kentucky last reported 0.01% of its portfolio in the stock. Renaissance Technology Lc holds 232,900 shares or 0.01% of its portfolio. Ubs Asset Management Americas Inc accumulated 22,699 shares or 0% of the stock. Moreover, Tudor Et Al has 0.01% invested in Acorda Therapeutics Inc (NASDAQ:ACOR) for 13,546 shares. Checchi Cap Advisers Ltd Co accumulated 16 shares or 0% of the stock. Blackrock Institutional Tru Company Na has 0.01% invested in the company for 1.30M shares. Pnc Finance Svcs Gp Incorporated has 7,712 shares for 0% of their US portfolio. Senzar Asset Mngmt Ltd holds 0% or 358,191 shares in its portfolio. Spark Inv Mngmt Limited Liability Co accumulated 0.7% or 292,400 shares. New York State Teachers Retirement Sys has 59,217 shares for 0% of their US portfolio. Benjamin F Edwards & Inc last reported 0% of its portfolio in the stock. Clinton Group has 35,802 shares for 0.04% of their US portfolio.
Insider Transactions: Since April 19, 2016, the stock had 0 buys, and 5 insider sales for $253,901 net activity. On Friday, May 13 the insider Hindman Andrew A. sold $126,885. Wasman Jane had sold 500 shares worth $13,660 on Friday, September 23. RAUSCHER STEVEN M sold 1,086 shares worth $30,224. 250 Acorda Therapeutics Inc (NASDAQ:ACOR) shares with value of $5,205 were sold by LAWRENCE DAVID. 1,488 shares were sold by Randall Lorin, worth $42,676 on Tuesday, April 19.
ACOR Company Profile
Acorda Therapeutics, Inc., incorporated on March 17, 1995, is a biopharmaceutical company. The Firm is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. The Company’s commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. The Company’s research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. The Company’s Ampyra (dalfampridine) Extended Release Tablets, 10 milligrams, is used as a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, which are short-acting drugs for the management of spasticity, and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company’s pipeline of neurological therapies addresses a range of disorders, including MS, Parkinson’s disease, chronic post-stroke walking deficits (PSWD), epilepsy and migraine.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.